Evidence map›Paper›PMID 36350790›Full record

ArticleRNA biology2022

A novel strategy for orthogonal genetic regulation on different RNA targeted loci simultaneously.

Yongjian Guo, Liang Wang, Zhen Qi, Yu Liu, Kun Tian, Huanran Qiang, Pei Wang, Guohua Zhou, Xiaobo Zhang, Shu Xu

Open access · goldAbstract read
In one paragraph

Article in RNA biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Yongjian GuoSchool of Basic Medical Science and Clinical Pharmacy, China Pharmaceutical University, Nanjing, 210000, China.
Liang WangSchool of Basic Medical Science and Clinical Pharmacy, China Pharmaceutical University, Nanjing, 210000, China.
Zhen QiSchool of Basic Medical Science and Clinical Pharmacy, China Pharmaceutical University, Nanjing, 210000, China.
Yu LiuSchool of Basic Medical Science and Clinical Pharmacy, China Pharmaceutical University, Nanjing, 210000, China.
Kun TianSchool of Basic Medical Science and Clinical Pharmacy, China Pharmaceutical University, Nanjing, 210000, China.
Huanran QiangSchool of Basic Medical Science and Clinical Pharmacy, China Pharmaceutical University, Nanjing, 210000, China.
Pei WangSchool of Basic Medical Science and Clinical Pharmacy, China Pharmaceutical University, Nanjing, 210000, China.
Guohua ZhouDepartment of Pharmacology, Jinling Hospital, Medical School, Nanjing University, Nanjing, 210000, China.
Xiaobo ZhangSchool of Basic Medical Science and Clinical Pharmacy, China Pharmaceutical University, Nanjing, 210000, China.
Shu XuSchool of Basic Medical Science and Clinical Pharmacy, China Pharmaceutical University, Nanjing, 210000, China.ORCID 0000-0003-4608-8610
China Pharmaceutical University · CNNanjing General Hospital of Nanjing Military Command · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

No current RNA-targeted interference tools have been reported to simultaneously up and down-regulate different gene expressions. Here we characterized an RNA-targeted genetic regulatory strategy composed of a flap endonuclease 1 (FEN1) and specific mis-hairpin DNA probes (mis-hpDNA), to realize the orthogonal genetic regulation. By targeting mRNA, the strategy hindered the translation and silenced genes in human cells with efficiencies of ~60%. By targeting miRNA, the strategy prevented the combination of miRNA to its specific mRNA and increased this mRNA expression by about 3-folds. In combination, we simultaneously performed

Indexed as

MicroRNAsGene Knockdown TechniquesHumansRNA InterferenceRNA, MessengerSignal TransductionMicroRNAsRNA, MessengerFEN1miRNAmis-hpDNAmRNAOrthogonal genetic regulating

Identifiers

PMID36350790
PMCPMC9648401
OpenAlexW4308627705

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.